Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: The citrate transporter SLC13A5 as a therapeutic target for kidney disease: evidence from Mendelian randomization to inform drug development

Fig. 2

Mendelian randomization estimates for the association of genetically proxied SLC13A5 inhibition with kidney traits. Mendelian randomization estimates are scaled per 1-standard deviation (SD) increase in plasma citrate through genetically proxied SLC13A5 inhibition. The units for the BUN, creatinine-eGFR, cystatin C-eGFR and uACR are SD change in log transformed levels. The units for CKD and microalbuminuria are log odds ratio. Raw p values are presented. BUN: blood urea nitrogen, chronic kidney disease; eGFR: estimated glomerular filtration rate, urine albumin-creatinine ratio

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us